New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Stocks in this Quantisnow insightHealth Care
Historical context for GILD
Across the 25 sessions after earlier GILD headlines, the stock closed higher 16 times and lower 9 times, with a median move of 0.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GILD | SPY |
|---|---|---|---|
| May 22, 2026 | FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC | +3.0% | +0.4% |
| May 21, 2026 | FDA Approval for BIKTARVY issued to GILEAD SCIENCES INCand 2 other headlines that session | -0.1% | +0.2% |
| May 20, 2026 | Gilead Sciences upgraded by Maxim Group with a new price target | +0.1% | +1.0% |
| May 15, 2026 | Gilead Prices $3 Billion of Senior Unsecured Notes | -1.9% | -1.2% |
| May 13, 2026 | Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 | -1.4% | +0.6% |
| May 8, 2026 | Gilead Sciences Announces First Quarter Financial Results | -2.0% | +0.8% |
Quantisnow market dataNASDAQ
GILD
Gilead Sciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1992
Get push alerts for GILD
Full GILD profile on Quantisnow Follow GILD and get a push notification the moment its next story breaks.